Breakthrough in Alzheimer's Treatment: The Efficacy of Leqembi

Alzheimer's disease, a neurodegenerative disorder characterized by the accumulation of amyloid or tau proteins in the brain, has seen a significant stride in its treatment options. The fundamental approach lies in eliminating amyloid, and a groundbreaking injectable medication was unveiled in January of this year. Known as Leqembi, this drug has shown promise in reducing cognitive decline in Alzheimer's patients.

In a study involving 1,500 Alzheimer's patients who received Leqembi injections, a remarkable 18% improvement in cognitive function was observed over an 18-month period. The medication demonstrated its efficacy in removing amyloid plaques, a hallmark of Alzheimer's pathology. This marks a new phase in treatment, distinct from medications that merely delay progression.

However, it's essential to note that Leqembi is not suitable for all Alzheimer's patients. It is primarily targeted at those in the early stages of the disease or with relatively mild symptoms that do not significantly impact daily life. Moreover, the associated cost of approximately 35 million won per year raises concerns about accessibility.

Expected to be introduced in South Korea by late next year or early 2025, the high cost prompts efforts from the Korean Dementia Society to address potential financial barriers.

Breakthrough in Alzheimer's Treatment: The Efficacy of Leqembi

Long-Term Considerations in Dementia Medication Usage

Administering dementia medication mirrors the lifelong commitment seen with hypertension or diabetes drugs. Despite potential side effects, discontinuing the medication is not advisable, as these drugs primarily serve to delay progression rather than provide a cure.

Unlike medications for acute conditions, dementia drugs necessitate ongoing usage, reinforcing the concept of maintaining them throughout one's life. A critical distinction emerges between the perception of ineffectiveness and the necessity of continuous medication. Ceasing medication prematurely can lead to exacerbation of symptoms and the emergence of disruptive behaviors.

Dementia medications, particularly those belonging to the donepezil class, maintain their effectiveness by adhering to consistent dosages. Adjusting dosages based on symptom improvement is not recommended, emphasizing the importance of a steady regimen.

In instances where the maximum dosage fails to yield desired outcomes, supplementary drugs like memantine may be incorporated into a combination therapy approach. This illustrates the intricate nature of dementia treatment and the need for personalized strategies tailored to individual patient responses.

In conclusion, the introduction of Leqembi heralds a new era in Alzheimer's treatment, emphasizing the importance of sustained medication usage. Balancing the potential benefits against the financial considerations remains a challenge, underscoring the ongoing efforts to enhance accessibility and affordability in the realm of dementia care.